Use of Adelmidrol in the Treatment of Epithelial Dysfunctions

Abstract

Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This is a continuation application of U.S. application Ser. No. 14 / 793,165, filed on Jul. 7, 2015, published; which claims priority to Italian Application Number MI2014A001245, filed on Jul. 8, 2014. The entire disclosures of the aforementioned applications are expressly incorporated herein by reference for all purposes.DESCRIPTION[0002]Technical Field of Invention[0003]The object of the present invention is Adelmidrol in the treatment of epithelial dysfunctions.[0004]Background Art[0005]Palmitoylethanolamide (PEA) is an endogenous lipid N-acylamidic substance of which an effect on neuroinflammation and pain has been widely demonstrated [Calignano A. et al Europ. J. Pharmacol. 2001; 419:191-198; Skaper S. D. et al Mol Neurobiol. 2013; 48:340-352; Skaper S. D. et al. Inflammopharmacology. 2014; 22:79-94]. On the pharmacological level, the increase in the endogenous levels of PEA is currently considered important to determine the control of...

AI Technical Summary

Benefits of technology

The present patent describes the discovery of a substance called Adelmidrol that can increase the levels of PEA (a neuropeptide) in epithelial cells without affecting the enzymes that break down PEA. This allows for the effective treatment of various epithelial tissue dysfunctions in humans and animals. The patent also describes pharmaceutical formulations containing Adelmidrol, as well as other ingredients such as oxazoline derivatives of Palmitoylethanolamide, anti-microbial agents, trans-traumatic acid, and hyaluronic acid or derivatives thereof. Overall, the patent provides a novel approach for treating epithelial tissue dysfunctions and offers potential benefits for a wide range of human and animal healthcare applications.

Problems solved by technology

However, this method implies a serious problem since blocking the degradation of PEA through the block of specific degradation enzymes corresponds to preventing reuse, which is essential, of the PEA components, ethanolamine and palmitic acid, needed to return the phospholipid from which PEA is biologically synthesized “on demand” to the cell, through the phospholipid synthesis.

There is also the problem that, while the systemic oral administration of PEA in micronized or ultramicronized form has been found to be effective and safe [Skaper S. D. et al Inflammopharmacol.

2013; 13:237-55], the topical use, in the form of a cream or solution, is very difficult and poorly effective because of the difficulty of producing, in this manner, pharmacologically effective amounts of PEA as a result of the high hydrophobicity of this important lipid molecule.

Images